CardioDx Raises $60M

Xconomy San Francisco — 

CardioDx, the Palo Alto, CA-based developer of blood-based genetic tests for cardiovascular disease, said today it has raised $60 million in equity financing. Longitude Capital, JP Morgan, Acadia Woods Partners, Artiman Ventures, and Bright Capital, the venture arm of RU-COM, participated in the round. CardioDx said it plans to use the cash to win greater reimbursement coverage for its Corus CAD product for coronary artery disease, and for more product development.